Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Advertising
 

EquipNet Auction: Sell your surplus on our global marketplace: No cost to list equipment!

Check Out Our Newest Cartoon: "Milestones in Diabetes"

North American Biotech Roadshow Featuring Grad Students, Post-Docs & Start-Up “Do’s & Don’ts”


Washington Life Science Industry Directory

EquipNet Auction: Sell your surplus on our global marketplace: No cost to list equipment!

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2022 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

Resolve Therapeutics, LLC


Resolve Therapeutics, LLC
454 N 34th Street
Seattle, WA 98103
 
 
Phone: (208) 727-7010
Year Established:  2010
Employees: 6
Main Contact: James Posada, Ph.D., MBA, CEO & Co-Founder
 
Other Contacts:  Peter Kiener, D. Phil, Chairman
Chris Gabel, Ph.D., CSO
 
Company Description
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of RSLV-132, its novel targeted biologic therapy. RSLV-132 represents a new approach to inhibiting the production of interferon-alpha at a proximal step in the inflammatory cascade. A multitude of evidence points to interferon-alpha as a critical mediator of the inflammation present in lupus patients. Development efforts in this field are greatly enhanced by the recent clinical validation of a biomarker called the “interferon signature” which tracks the activation level of the interferon pathway in lupus patients. The interferon signature provides a valuable pharmacodynamic endpoint which greatly enhances the early clinical evaluation of drugs acting to inhibit the interferon pathway. RSLV-132 is currently in advanced preclinical development, and Resolve expects to begin human clinical studies with this compound in the near future.


Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2022 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

WashingtonLifeScience.com is owned and published by Info.Resource, Inc.